Last reviewed · How we verify

NCT00311870

Renoprotective Effect of Nisoldipine and Lisinopril in Type 1 Diabetic Nephropathy

Completed Phase 4 Last updated 4 April 2006
What this trial tests

Phase 4 trial testing nisoldipine in Diabetic Nephropathy in 52 participants. Completed in 1 April 1999.

Timeline
1 March 1993
1 April 1999

Quick facts

Lead sponsorSteno Diabetes Center Copenhagen
PhasePhase 4
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposetreatment
Enrollment52
Start date1 March 1993
Estimated completion1 April 1999
Sites1 location across Denmark

Drugs / interventions tested

Conditions studied

Sponsor

Steno Diabetes Center Copenhagen — full company profile →

Who can join

Adults 18 to 55, any sex, with Diabetic Nephropathy. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Sponsor's own description

The aim of the study was to compare the renoprotective effect of a long acting calcium antagonist (nisoldipine) with an angiotensin converting enzyme inhibitor (lisinopril)in type 1 diabetic patients with diabetic kidney disease. In total, 51 patients were randomised to treatment with one of these drugs for 4 years. Changes in kidney function, blood pressure and urinary excretion of albumin were measured every 6 months

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Diabetic Nephropathy

Currently open trials in the same condition.

Other Steno Diabetes Center Copenhagen trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00311870.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing